UC's custom 3D-printed skull implants go global
December 13, 2019
Article has no nextliveshere tags assigned
Article has no topics tags assigned
Article has no colleges tags assigned
Description is empty
Article has no audiences tags assigned
Article has no units tags assigned
Contacts are empty
These messages will display in edit mode only.
Researchers at the University of Cincinnati are leading the local arm of a study looking at ways to test for chemosensitivity in brain tumor stem cells to determine treatment response and outcomes for patients.
The primary site for the clinical trial is Marshall University in West Virginia, but Nicholas Marko, MD, director of the UC Brain Tumor Center, is leading the study locally.
“We are collecting tumor tissue from our patients and sending it to our collaborators at Marshall,” says Marko, who is also an associate professor of neurosurgery at the UC College of Medicine and a member of both the Gardner Neuroscience and Cancer Institutes. “These researchers grow stem cells from the tumor and then try to kill those cells with a number of chemotherapy drugs. The therapy that works best, based on these outcomes, is the patient’s designated study drug.”
Marko says when glioblastoma, an extremely malignant form of brain tumor, recurs in patients, the treatment options are often minimal, as surgery and radiation are not usually a possibility.
“In this study, patients with recurrent glioblastoma will receive standard therapy, including surgery if the tumor can be removed, and for the chemotherapy portion of their treatment, participants will be randomized between treatments chosen by the physician—standard cancer treatments—or the personally-selected, chemosensitivity drug. The goal is to see if this personalized therapy is more effective than standard of care.
“The idea is similar to when we test for bacterial sensitivity against antibiotics, in case of a bacterial infection. The test, in this case, uses sample specimens obtained following surgery for the treatment of brain cancer.”
Marko says that participants will be assessed by either brain MRI with contrast or CT scans at two to three month intervals after therapies are administered.
“The hope is that this study will lead to more personalized, targeted treatment for patients with a very serious cancer,” he says.
This study is being funded by ChemoID. Marko cites no conflict of interest.
*Photo credit: Colleen Kelley / University of Cincinnati, Communication Services
To find out more about enrolling in the study, call 513-418-2282.
December 13, 2019
December 13, 2019
December 12, 2019
Angela Clark and her research team started noticing an unprecedented trend — an increasing number of people who needed emergency services after receiving naloxone (Narcan), an opioid antagonist used for complete or partial reversal of opioid overdose. The overdose victims were arriving outside the emergency department, which meant nurses were walking outside the emergency department to aid these incapacitated patients. Clark knew nurses had not been trained to respond to these situations, and their safety was at risk. Angela Clark, a professor of nursing at the University of Cincinnati, decided to develop a training program to teach nurses how to protect themselves while leveraging their medical expertise. “Nurses are trained to put the patient first, while police are trained to put safety first,” said Clark, whose team launched the Be-SAFE program in 2017.